 |
5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine hydrochloride |
|---|---|
| Trade Name | |
| Orphan Indication | Progressive supranuclear palsy |
| USA Market Approval | USA |
| USA Designation Date | 2011-04-18 00:00:00 |
| Sponsor | Mithridion, Inc.;505 Science Drive;Madison, Wisconsin, 53711 |
